title: Accelerated radiotherapy and larynx preservation in favorable-risk patients with T2 or worse hypopharyngeal cancer.
abstract: OBJECTIVE
  To evaluate the advantage of accelerated fractionation radiotherapy for patients with hypopharyngeal cancer requiring total laryngectomy.
  
  
  METHODS
  Seventy patients with previously untreated, technically resectable hypopharyngeal cancer who received larynx-preserving treatment with radiotherapy between April 1992 and June 2004 were analyzed. No patients had previous history of other malignancy or poor performance status that would possibly affect the outcomes. A total RT dose of > or = 60 Gy/6 weeks was determined depending on the tumor clearance during treatment before December 1998, and fixed to 70 Gy in all patients thereafter. Accelerated fractionation (70 Gy/<49 days) was completed in 35 patients during the latter period. Concomitant platinum-based chemotherapy was used in 41 patients after May 1998.
  
  
  RESULTS
  Local control rates at 2 years were 72 and 68% for patients with T2 and T3/T4 disease, respectively. Patients who had received 70 Gy/<49 days achieved a better local control rate than those who had received other, more conservative total dose/overall treatment time with statistical significance (91% versus 50% at 2 years, P < 0.001). Multivariate analysis involving 70 Gy/<49 days of radiotherapy, T-classification (T2 versus T3/4), and use of chemotherapy revealed that administering 70 Gy/<7 weeks was the only independent prognostic factor (P = 0.007) for better local control.
  
  
  CONCLUSIONS
  Our experience in radiotherapy for hypopharyngeal cancer mirrored the results of previously conducted large randomized trials for various head and neck cancers. Encouraging local control in this study warrants prospective study to test the long-term oncological and functional outcome of larynx-preserving treatment in patients with advanced but resectable volume of this disease.
authors.affiliation: Radiation Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. mkawashi@east.ncc.go.jp
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Kawashima
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Hayashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Tahara
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Yamazaki
authors.forename: Masakazu
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Satoko
authors.initials: S
authors.lastname: Arahira
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogino
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D007830:Larynx; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage; D016879:Salvage Therapy; D005641:Tegafur / Q000627:therapeutic use; D016896:Treatment Outcome; D014498:Uracil / Q000627:therapeutic use
chemical_list: D005641:Tegafur; D014498:Uracil; D002945:Cisplatin